|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM186160216 |
| 003 |
DE-627 |
| 005 |
20231223173732.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2009 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.12.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0621.xml
|
| 035 |
|
|
|a (DE-627)NLM186160216
|
| 035 |
|
|
|a (NLM)19188092
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Parameswaran, Reshmi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.05.2009
|
| 500 |
|
|
|a Date Revised 13.04.2009
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulated immune responses mediated by T and B cells. A tolerogenic peptide, designated hCDR1, ameliorated the serological and clinical manifestations of SLE in mouse models of lupus. We investigated the role of B-cell activating factor (BAFF) in the beneficial effects of hCDR1. BAFF production was reduced in hCDR1-treated mice in association with diminished production of dsDNA-specific autoantibodies and proteinuria levels. In addition, IFN-gamma and IL-10, which induce BAFF secretion, were down-regulated in hCDR1-treated mice. The reduced levels of BAFF correlated with a lower rate of maturation and differentiation of B cells, and with a decrease in integrin expression and anti-apoptotic gene expression by B cells. Moreover, BAFF signaling through the NF-kB pathways was inhibited in hCDR1-treated mice. Thus, down-regulation of BAFF plays a role in the mechanism of action by which hCDR1 ameliorates lupus manifestations
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Autoantigens
|2 NLM
|
| 650 |
|
7 |
|a B-Cell Activating Factor
|2 NLM
|
| 650 |
|
7 |
|a CDR1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Integrins
|2 NLM
|
| 650 |
|
7 |
|a Nerve Tissue Proteins
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Ben David, Hava
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sharabi, Amir
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zinger, Heidy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mozes, Edna
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 131(2009), 2 vom: 15. Mai, Seite 223-32
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:131
|g year:2009
|g number:2
|g day:15
|g month:05
|g pages:223-32
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.12.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 131
|j 2009
|e 2
|b 15
|c 05
|h 223-32
|